News | March 24, 2015

Study Finds Medication Superior to Stents for Narrowed Artery Within the Brain

Balloon-expandable stents found to increase risk of stroke or transient ischemic attack within one year

JAMA, intracranial arterial stenosis, balloon expandable stents, medication

March 24, 2015 — A study in the March 24/31 issue of JAMA found that using balloon-expandable stents to treat symptomatic intracranial arterial stenosis resulted in an increased risk of stroke or transient ischemic attack (TIA). The study results support the use of medical therapy (clopidogrel and aspirin) as an alternative to balloon-expandable stents.

Intracranial arterial stenosis (narrowing of an artery inside the brain) is a common cause of stroke worldwide. The recurrent stroke risk with severe symptomatic intracranial stenosis may be as high as 23 percent at 1 year, despite medical therapy, according to background information in the article.

Osama O. Zaidat, M.D., M.S., of the Medical College of Wisconsin/Froedtert Hospital, Milwaukee, and colleagues randomly assigned 112 patients with symptomatic intracranial stenosis (narrowing of 70 percent or greater) to receive a balloon-expandable stent plus medical therapy (stent group; n = 59) or medical therapy alone (medical group; n = 53). Medical therapy consisted of clopidogrel (75 mg daily) for the first 3 months after enrollment and aspirin (81-325 mg daily) for the study duration.

This international trial (VISSIT) enrolled patients from 27 sites (January 2009-June 2012) with last follow-up in May 2013. Enrollment was halted by the sponsor after negative results from another trial prompted an early analysis of outcomes, which suggested futility after 112 patients of a planned sample size of 250 were enrolled.

The 30-day safety end point of any stroke within 30 days or hard TIA within 2 to 30 days was 9.4 percent (5/53) in the medical group and 24.1 percent (14/58) in the stent group; TIA was defined as a transient episode of neurological dysfunction caused by focal brain or retinal ischemia lasting at least 10 minutes but resolving within 24 hours. Ischemic stroke was observed in three patients (5.7 percent) in the medical group and in 10 patients (17.2 percent) in the stent group. Intracranial hemorrhage occurred in five patients (8.6 percent) in the stent group and in 0 in the medical group. The 1-year outcome of stroke or hard TIA occurred in more patients in the stent group (36.2 percent) vs the medical group (15.1 percent).

Thirty-day all-cause death was 3 of 58 patients (5.2 percent) in the stent group and 0 in the medical group. A measure of disability worsened in more patients in the stent group than in the medical group.

“These findings do not support the use of a balloon-expandable stent for patients with intracranial arterial stenosis,” the authors conclude.

For more information: www.media.jamanetwork.com

Related Content

NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...
Medication Alone May Not Eliminate Stroke Risk in Carotid Atherosclerotic Stenosis Patients
News | Stroke | October 31, 2018
Recent statin and medication advances have led some researchers to suggest surgical treatments for carotid stenosis...
iSchemaView RAPID Technology Now Installed in More Than 500 Stroke Centers
News | Stroke | August 28, 2018
iSchemaView announced that more than 575 stroke centers in 22 countries have selected the RAPID advanced imaging...
Breast feeding may help reduce the stroke risk in women. Katherine Fornell

Breast feeding may help reduce the stroke risk in women.

News | Stroke | August 22, 2018
Breastfeeding is not only good for babies, according to new research in the Journal of the American Heart Association....
iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
July 13, 2018 – iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAP
NewYork-Presbyterian Expands Mobile Stroke Treatment Unit Fleet
News | Stroke | June 11, 2018
NewYork-Presbyterian, in collaboration with Weill Cornell Medicine, Columbia University Irving Medical Center and the...
International Study Suggests Combination Therapy May Prevent Stroke in Certain People
News | Stroke | June 07, 2018
June 7, 2018 — Results from an international clinical trial show that combining...
The Vivistim device is similar to a pacemaker, which uses leads to electrically stimulate the brain. A new clinical trial at The Ohio State University Wexner Medical Center is examining use of this device for stroke rehabilitation.

A new clinical trial at The Ohio State University Wexner Medical Center is examining an implanted device that uses vagus nerve stimulation to help stroke patients regain motor function. The Vivistim device is similar to a pacemaker, which uses leads to electrically stimulate the brain. 

News | Stroke | May 09, 2018
May 9, 2018 — Stroke rehabilitation specialists at the The Ohio State University Wexner Medical Center are among the
Videos | Stroke | May 09, 2018
A new clinical trial at The Ohio State University Wexner Medical Center is examining an implanted device that uses va
Overlay Init